| ［1］ |
韦志明, 方汉军, 李中峰, 等. 痛风性膝关节炎的手术治疗进展［J/OL］. 中华关节外科杂志（ 电子版）, 2022, 16（ 3 ）: 343-347.
|
| ［2］ |
Dalbeth N, Gosling AL, Gaffo A, et al. Gout［J］. Lancet, 2021, 397（ 10287 ）: 1843-1855.
|
| ［3］ |
方宁远,吕力为,吕晓希,等.中国高尿酸血症相关疾病诊疗多学科专家共识（2023年版）［J］.中国实用内科杂志, 2023, 43（ 06 ）:461-480.
|
| ［4］ |
Cabău G, Crișan TO, Klück V, et al. Urate-induced immune programming: consequences for gouty arthritis and hyperuricemia ［J］.Immunol Rev, 2020, 294（ 1 ）: 92-105.
|
| ［5］ |
Wang C, Ma C, Gong L, et al. Macrophage polarization and its role in liver disease［J/OL］. Front Immunol, 2021, 12: 803037.DOI:10.3389/fimmu.2021.803037.
|
| ［6］ |
Bousoik E, Qadri M, Elsaid KA. CD44 receptor mediates urate crystal phagocytosis by macrophages and regulates inflammation in A murine peritoneal model of acute gout［J/OL］. Sci Rep, 2020, 10（ 1 ）: 5748. DOI:10.1038/s41598-020-62727-z.
|
| ［7］ |
Michalick L,Kuebler WM. TRPV4-a missing link between mechanosensation and immunity［J/OL］. Front Immunol, 2020, 11:413. DOI:10.3389/fimmu.2020.00413.
|
| ［8］ |
Lan Z, Chen L, Feng J, et al. Mechanosensitive TRPV4 is required for crystal-induced inflammation ［J］. Ann Rheum Dis, 2021, 80（ 12 ）: 1604-1614.
|
| ［9］ |
Silva CR, Saraiva AL, Rossato MF, et al. What do we know about toll-like receptors involvement in gout arthritis?［J］. Endocr Metab Immune Disord Drug Targets, 2023, 23（ 4 ）: 446-457.
|
| ［10］ |
Zhao J, WeiK, JiangP, etal. Inflammatory response to regulated cell death in gout and its functional implications［J/OL］. Front Immunol,2022, 13: 888306. DOI:10.3389/fimmu.2022.888306.
|
| ［11］ |
CoboI, Cheng A, Murillo-Saich J, et al. Monosodium urate crystals regulate a unique JNK-dependent macrophage metabolic and inflammatory response［J/OL］. Cell Rep, 2022, 38（ 10 ）: 110489.DOI:10.1016/j.celrep.2022.110489.
|
| ［12］ |
Liu L, Zhu L, LiuM, etal. Recent insights into the role of macrophages in acute gout［J/OL］. Front Immunol, 2022,13:955806.DOI:10.3389/fimmu.2022.955806.
|
| ［13］ |
Zhao L, Ye W, Zhu Y, et al. Distinct macrophage polarization in acute and chronic gout［J］. Lab Invest, 2022, 102（ 10 ）: 1054-1063.
|
| ［14］ |
Klück V, Cabău G, Mies L, et al. TGF-β is elevated in hyperuricemic individuals and mediates urate-induced hyperinflammatory phenotype in human mononuclear cells［J/OL］. Arthritis Res Ther,2023, 25（ 1 ）: 30. DOI:10.1186/s13075-023-03001-1.
|
| ［15］ |
Silvestre-Roig C, Fridlender ZG, Glogauer M, et al. Neutrophil diversity in health and disease［J］. Trends Immunol, 2019, 40（ 7 ）:565-583.
|
| ［16］ |
Papayannopoulos V. Neutrophil extracellular traps in immunity and disease［J］. Nat Rev Immunol, 2018, 18（ 2 ）: 134-147.
|
| ［17］ |
Huang J, Hong W, Wan M, et al. Molecular mechanisms and therapeutic target of NETosis in diseases［J/OL］. Med Comm, 2022,3（ 3 ）: e162. DOI:10.1002/mco2.162.
|
| ［18］ |
Tang H, Tan C, Cao X, et al. NFIL3 facilitates neutrophil autophagy,neutrophil extracellular trap formation and inflammation during gout via REDD1-dependent mTOR inactivation［J/OL］. Front Med,2021, 8: 692781. DOI:10.3389/fmed. 2021.692781.
|
| ［19］ |
Tan H, Li Z, Zhang S, et al. Novel perception of neutrophil extracellular traps in gouty inflammation［J/OL］. Int Immunopharmacol, 2023,115: 109642.DOI:10.1016/j.intimp.2022.109642.
|
| ［20］ |
Tatsiy O, Mayer TZ, de Carvalho Oliveira V, et al. Cytokine production and NET formation by monosodium urate-activated human neutrophils involves early and late events, and requires upstream TAK1 and syk［J/OL］. Front Immunol, 2019, 10: 2996.DOI:10.3389/fimmu.2019.02996.
|
| ［21］ |
Yin C, Liu B, Li Y, et al. IL-33/ST2 induces neutrophil-dependent reactive oxygen species production and mediates gout pain［J］.Theranostics, 2020, 10（ 26 ）: 12189-12203.
|
| ［22］ |
Reber LL, Gaudenzio N, Starkl P, et al. Neutrophils are not required for resolution of acute gouty arthritis in mice［J］. Nat Med, 2016, 22（ 12 ）: 1382-1384.
|
| ［23］ |
Garcia-Gonzalez E, Gamberucci A, LucheriniOM, et al. Neutrophil extracellular traps release in gout and pseudogout depends on the number of crystals regardless of leukocyte count［J］. Rheumatology,2021, 60（ 10 ）: 4920-4928.
|
| ［24］ |
Cumpelik A, Ankli B,Zecher D, et al. Neutrophil microvesicles resolve gout by inhibiting C5a-mediated priming of the inflammasome［J］. Ann Rheum Dis, 2016, 75（ 6 ）: 1236-1245.
|
| ［25］ |
Sharabi A,Tsokos GC. T cell metabolism: new insights in systemic lupus erythematosus pathogenesis and therapy［J］. Nat Rev Rheumatol, 2020, 16（ 2 ）: 100-112.
|
| ［26］ |
Wang B, Chen S, Qian H, et al. Role of T cells in the pathogenesis and treatment of gout［J/OL］. IntImmunopharmacol, 2020,88:106877. DOI:10.1016/j.intimp.2020.106877.
|
| ［27］ |
Zhao LJ, Wang H, Gao HY, et al. Increase in different peripheral effector T subsets in acute and chronic gout［J/OL］. TransplImmunol,2023, 76:101763. DOI:10.1016/j.trim.2022.101763.
|
| ［28］ |
Luo G, Yi T, Zhang G, et al. Increased circulating Th22 cells in patients with acute gouty arthritis: a CONSORT-compliant article［J/OL］. Medicine, 2017, 96（ 42 ）: e8329. DOI:10.1097/MD.0000000000008329.
|
| ［29］ |
Liu X, Li Y, Li Z, et al. A novel IgG1 monoclonal antibody against xanthine oxidase alleviates inflammation induced by potassium oxonate in mice［J］. Int J Biol Macromol, 2018, 112: 537-547.
|
| ［30］ |
Wang H, Xie L, Song X, et al. Purine-induced IFN-γ promotes uric acid production by upregulating xanthine oxidoreductase expression［J/OL］. Front Immunol, 2022, 13:773001. DOI:10.3389/fimmu.2022.773001.
|
| ［31］ |
Dai XJ, Tao JH, Fang X, et al. Changes of treg/Th17 ratio in spleen of acute gouty arthritis rat induced by MSU crystals［J］.Inflammation, 2018, 41（ 5 ）: 1955-1964.
|
| ［32］ |
Raucci F, Iqbal AJ, Saviano A, et al. IL-17A neutralizing antibody regulates monosodium urate crystal-induced gouty inflammation［J/OL］. Pharmacol Res, 2019, 147: 104351. DOI:10.1016/j.phrs.2019.104351.
|
| ［33］ |
Saviano A, Raucci F, Casillo GM, et al. Anti-inflammatory and immunomodulatory activity of Mangiferaindica L. reveals the modulation of COX-2/mPGES-1 axis and Th17/Tregratio［J/OL］. Pharmacol Res, 2022, 182:106283. DOI:10.1016/j.phrs.2022.106283.
|
| ［34］ |
Migliorini P, Italiani P, Pratesi F, et al. The IL-1 family cytokines and receptors in autoimmune diseases［J/OL］. Autoimmun Rev,2020, 19（ 9 ）: 102617. DOI:10.1016/j.autrev. 2020.102617.
|
| ［35］ |
Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity［J］. Immunol Rev, 2018, 281（ 1 ）: 8-27.
|
| ［36］ |
Choe JY, Jung HY, Park KY, et al. Enhanced p62 expression through impaired proteasomal degradation is involved in caspase-1 activation in monosodium urate crystal-induced interleukin-1β expression［J］. Rheumatology （ Oxford ）, 2014, 53（ 6 ）: 1043-1053.
|
| ［37］ |
Heilig R, Dick MS, Sborgi L, et al. The Gasdermin-D pore acts as a conduit for IL-1β secretion in mice［J］. Eur J Immunol, 2018, 48 （ 4 ）:584-592.
|
| ［38］ |
Galvão I, Dias ACF, Tavares LD, et al. Macrophage migration inhibitory factor drives neutrophil accumulation by facilitating IL-1β production in a murine model of acute gout［J］. J Leukoc Biol, 2016,99（ 6 ）: 1035-1043.
|
| ［39］ |
Gross O, Yazdi AS, Thomas CJ, et al. Inflammasome activators induce interleukin-1α secretion via distinct pathways with differential requirement for the protease function of caspase-1［J］.Immunity, 2012, 36（ 3 ）: 388-400.
|
| ［40］ |
Rider P, Carmi Y, Guttman O, et al. IL-1α and IL-1β recruit different myeloid cells and promote different stages of sterile inflammation［J］. J Immunol, 2011, 187（ 9 ）: 4835-4843.
|
| ［41］ |
Fattori V, Staurengo-Ferrari L, Zaninelli TH, et al. IL-33 enhances macrophage release of IL-1β and promotes pain and inflammation in gouty arthritis［J］. Inflamm Res, 2020, 69（ 12 ）: 1271-1282.
|
| ［42］ |
Shang K, Wei Y, Su Q, et al. IL-33 ameliorates the development of MSU-induced inflammation through expanding MDSCs-like cells［J/OL］. Front Endocrinol, 2019, 10: 36. DOI:10.3389/fendo.2019.00036.
|
| ［43］ |
Duan L, Huang Y, Su Q, et al. Potential of IL-33 for preventing the kidney injury via regulating the lipid metabolism in gout patients［J］. J Diabetes Res, 2016, 2016: 1028401.DOI:10.1155/2016/1028401.
|
| ［44］ |
Liu L, Xue Y, Zhu Y, et al. Interleukin 37 limits monosodium urate crystal-induced innate immune responses in human and murine models of gout［J］. Arthritis Res Ther, 2016, 18（ 1 ）: 268.DOI:10.1186/s13075-016-1167-y.
|
| ［45］ |
Ding L, Li H, Sun B, et al. Elevated interleukin-37 associated with tophus and pro-inflammatory mediators in Chinese gout patients［J/OL］. Cytokine, 2021, 141: 155468. DOI:10.1016/j.cyto.2021.155468.
|
| ［46］ |
Zeng M, Dang W, Chen B, et al. IL-37 inhibits the production of pro-inflammatory cytokines in MSU crystal-induced inflammatory response［J］.Clin Rheumatol, 2016, 35（ 9 ）: 2251-2258.
|
| ［47］ |
KlückV, van DeurenRC, Cavalli G, et al. Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout［J］. Ann Rheum Dis, 2020, 79（ 4 ）: 536-544.
|
| ［48］ |
Zhao L, ZhaoT, Yang X, et al. IL-37 blocks gouty inflammation by shaping macrophages into a non-inflammatory phagocytic phenotype［J］. Rheumatology, 2022, 61（ 9 ）: 3841-3853.
|
| ［49］ |
杨智坚, 李奇. 白细胞介素-37与骨关节炎性疾病的研究进展［J/CD］. 中华关节外科杂志（ 电子版 ）, 2019, 13（ 2 ）: 200-205.
|